drugset
drugset / Trial / NCT04533828

68Ga-FAPI PET/CT in Liver Fibrosis Patients

NCT04533828 ↗

Phase 0 Unknown 50 enrolled First Affiliated Hospital of Fujian Medical University
NaSingle-groupOpen-labelDiagnostic

Summary

To evaluate the potential value of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis and prognosis in liver fibrosis disease.

Timeline

Start
2020-09-01
Primary completion
2023-08-31
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-FAPI-04 Diagnostic / imaging agent — Intravenous

Indications

fibrotic liver disease